| Literature DB >> 27597634 |
Wing-Po Chak1,2, Raymond Wai-Ming Lung1,2, Joanna Hung-Man Tong1,2, Sylvia Yat-Yee Chan1,2, Samantha Wei-Man Lun1,2, Sai-Wah Tsao3, Kwok-Wai Lo1,2, Ka-Fai To1,2,4.
Abstract
In our previous whole-transcriptome sequencing analysis, downregulation of a long non-coding RNA, maternally expressed gene 3 (MEG3), was identified in NPC samples. This finding suggests the possible role of MEG3 as a tumor suppressor in this distinctive disease. In the present study, two MEG3 variants, AF119863 (MEG3-AF) and BX247998 (MEG3-BX), were found abundantly expressed in a normal nasopharyngeal epithelial cell line, NP69. Significant downregulation of MEG3-AF was further verified in a panel of NPC samples including xenografts and primary biopsies. MEG3 is an imprinted gene located within chromosome 14q32, a common deleted region in NPC. Both DNA copy number loss and aberrant promoter methylation contributed to MEG3 inactivation. Interestingly, MEG3 expression could successfully be rescued by the treatment of a demethylation agent. Besides, ectopic expression of MEG3 in NPC cell lines resulted in considerable repression of in vitro anchorage-independent growth and in vivo tumorigenicity, in addition to significant inhibition in cell proliferation, colony formation, and induction of cell cycle arrest. Finally, we revealed the association between MEG3 activity and the p53 signaling cascade. Our findings characterize MEG3 as a tumor suppressive long non-coding RNA in NPC and encourage the development of precise long non-coding RNA-targeted epigenetic therapy against this malignancy.Entities:
Keywords: MEG3; NPC; lncRNA; promoter hypermethylation; tumor suppression
Mesh:
Substances:
Year: 2016 PMID: 27597634 DOI: 10.1002/mc.22569
Source DB: PubMed Journal: Mol Carcinog ISSN: 0899-1987 Impact factor: 4.784